Gastrointestinal Mechanisms Underlying the Cardiovascular Effect of Metformin
Metformin, the most widely prescribed drug therapy for type 2 diabetes, has pleiotropic benefits, in addition to its capacity to lower elevated blood glucose levels, including mitigation of cardiovascular risk. The mechanisms underlying the latter remain unclear. Mechanistic studies have, hitherto,...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Book |
| Published: |
MDPI AG,
2020-11-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_a8daeecc10fb48a6bbfa2297e4eae7e7 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Malcolm J. Borg |e author |
| 700 | 1 | 0 | |a Christopher K. Rayner |e author |
| 700 | 1 | 0 | |a Karen L. Jones |e author |
| 700 | 1 | 0 | |a Michael Horowitz |e author |
| 700 | 1 | 0 | |a Cong Xie |e author |
| 700 | 1 | 0 | |a Tongzhi Wu |e author |
| 245 | 0 | 0 | |a Gastrointestinal Mechanisms Underlying the Cardiovascular Effect of Metformin |
| 260 | |b MDPI AG, |c 2020-11-01T00:00:00Z. | ||
| 500 | |a 10.3390/ph13110410 | ||
| 500 | |a 1424-8247 | ||
| 520 | |a Metformin, the most widely prescribed drug therapy for type 2 diabetes, has pleiotropic benefits, in addition to its capacity to lower elevated blood glucose levels, including mitigation of cardiovascular risk. The mechanisms underlying the latter remain unclear. Mechanistic studies have, hitherto, focused on the direct effects of metformin on the heart and vasculature. It is now appreciated that effects in the gastrointestinal tract are important to glucose-lowering by metformin. Gastrointestinal actions of metformin also have major implications for cardiovascular function. This review summarizes the gastrointestinal mechanisms underlying the action of metformin and their potential relevance to cardiovascular benefits. | ||
| 546 | |a EN | ||
| 690 | |a metformin | ||
| 690 | |a cardiovascular | ||
| 690 | |a gastrointestinal | ||
| 690 | |a mechanisms | ||
| 690 | |a bile acids | ||
| 690 | |a gut microbiota | ||
| 690 | |a Medicine | ||
| 690 | |a R | ||
| 690 | |a Pharmacy and materia medica | ||
| 690 | |a RS1-441 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Pharmaceuticals, Vol 13, Iss 11, p 410 (2020) | |
| 787 | 0 | |n https://www.mdpi.com/1424-8247/13/11/410 | |
| 787 | 0 | |n https://doaj.org/toc/1424-8247 | |
| 856 | 4 | 1 | |u https://doaj.org/article/a8daeecc10fb48a6bbfa2297e4eae7e7 |z Connect to this object online. |